Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.31 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.31 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21324002 | 0.92 | CES2 (0.31) | CES2CA12CA1CA2CA9 | |
| SCHEMBL22907293 | 0.92 | CES2 (0.31) | CES2CA12CA1CA2CA9 | |
| SCHEMBL27341113 | 0.89 | CES2 (0.33) | CES2CA12CA1CA2CA9 | |
| SCHEMBL20115513 | 0.86 | CES2 (0.36) | CES2CA12CA1CA2CA9 | |
| SCHEMBL20628161 | 0.86 | CA12 (0.37) | CES2CA12CA1CA2CA9 | |
| SCHEMBL24835898 | 0.84 | CA12 (0.35) | CA12CA1CA2CA9KDM5A | |
| SCHEMBL24709510 | 0.82 | CA12 (0.34) | CES2CA12CA1CA2CA9 | |
| SCHEMBL20778802 | 0.81 | CA12 (0.33) | CES2CA12CA1CA2CA9 | |
| SCHEMBL23766685 | 0.80 | CA12 (0.37) | CES2CA12CA1CA2CA9 | |
| SCHEMBL24836047 | 0.80 | CA12 (0.36) | CA12CA1CA2CA9KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364223-A1 | CORONAVIRUS VACCINE | CureVac SE (DE) | 2023-11-16 | — | — | US | disclosed |
| US-20220133908-A1 | CODING RNA ADMINISTERED INTO THE SUPRACHOROIDAL SPACE IN THE TREATMENT OF OPHTHALMIC DISEASES | CUREVAC AG (DE) | 2022-05-05 | — | — | US | disclosed |
| US-20210198649-A1 | NOVEL NUCLEIC ACID MOLECULES | CUREVAC AG (DE) | 2021-07-01 | — | — | US | disclosed |
| US-20200163878-A1 | LIPID NANOPARTICLE MRNA VACCINES | CureVac SE (DE) | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133908-A1 | CODING RNA ADMINISTERED INTO THE SUPRACHOROIDAL SPACE IN THE TREATMENT OF OPHTHALMIC DISEASES | MTREX, NSUN3, SYNCRIP | CES2 2524/4885CA12 1595/4885CA1 3276/4885 |
| US-20210198649-A1 | NOVEL NUCLEIC ACID MOLECULES | TLR9, MICA, HLA-DRB1 | CES2 4787/4885CA12 725/4885CA1 1805/4885 |
| US-20230364223-A1 | CORONAVIRUS VACCINE | ACE2, LNPEP, ACE | CES2 2791/4885CA12 1113/4885CA1 4089/4885 |
| US-20200163878-A1 | LIPID NANOPARTICLE MRNA VACCINES | RNMT, PLIN3, SARNP | CES2 4392/4885CA12 1306/4885CA1 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.